CHARACTERIzATION of CD4 + T LYMPHOCYTE FROM BONE MAROW STEM CELL USING INDIRECT IMMUNOFLUORESENCE FOR HIV & AIDS TREATMENT
Downloads
Acquired immune deficiency syndrome (AIDS) is caused by Human Immunodeficiency Virus (HIV). At the beginning of infection, gp120 virus interacts with CD4 receptor at the surface of the target cell. The interaction between gp120 and CD4 leads to the occurrence of the binding of specific chemokine receptor CXCR4 and CCR5, which are also present on the membrane of the target cell. Therefore, CCR5 and CXCR4 also determine the fate of the target cell. It is the performance of CCR5 and CXCR4, guided by controlling gene that determines susceptibility or resistance to HIV infection. Coding gene CCR5 may mutate to become protective or resistant against HIV infection. In homozygote individuals, it tends to be resistant against infection, while in heterozygote individuals it tends to be susceptible to HIV infection. Objective: To characterize TCD4 lymphocyte in the next that is resistant against HIV infection by using gene therapy deletion 32 CCR5 to use for HIV & AIDS treatment. Method: Sample collection, mononucleated cell collection, lymphocyte
culture, CD4 identification, CCR5 variance analysis, co-cultivation with PBMC HIV and comparison to control. Result: This study was performed in several steps, such as mononucleated cell isolation, followed with cell culture, lymphocyte purification, lymphocyte and CD4 expression identification. Conclusion: Lymphocyte T CD4 had been mature after seven passages, once passage is about 5 days so for maturity lymphocyte T CD4 need 35 days and that cell as be candidate to resistant against HIV infection by using gene therapy
deletion 32 CCR5 to use for HIV & AIDS treatment.
Effect of gp120 on glutatione peroxidase activity in cortical cultures
and the interaction with steroid hormones. J Neurochem 81: 1–24.
2. Dinsmore J, Ratliff J, Deacon T (1996). Embryonic stem cell
differentiated in vitro as a novel source of cells for transplantation.
Cell Transplant, 5: 131–43.
3. Folks TM, Hart CE (1997). The Life Cycle of Human Immunodeficiency Virus Type 1. In: AIDS. Fourth Edition. Editors: DeVita VT, Hellman S, Rosernbrk SA. Lippincott – Raven, Philadelphia, pp. 29–43.
4. Hirschel B (2003). HIV infection. In : Infectious diseases in 30 days. Editor: Southwick FS. McGraw-Hill, Medical Publishing Division,
USA, p. 477–524.
5. Jaroslaw C, Cornelia W, Alexandra R (2003). Potential of embryonic and adult stem cells in vitro. Biol Chem, 384: 1391–409.
6. Koolman J, Rohm KH (2001). Daur Hidup Virus HIV. Dalam: Atlas
Berwarna dan Teks Biokimia. Edisi Alih Bahasa : Wanandi SI. Editor:
Sadikin. Penerbit Hipokrates, Jakarta, p. 358–359.
7. Ledru E, Lecoeur H, Garcia S, Debord T, Gougeon ML (1998).
Differential susceptibility to activation-induced apoptosis among
peripheral Th1 subsets: Correlation with Bcl-2 expression and
consequences for AIDS pathogenesis. The Journal of Immunology.
160: 3194–3206.
8. Levinson W, Jawetz E (2003). Human Immunodeficiency Virus.
In: Medical Microbiology and Immunology. Seventh Edition. Editor: Levinson W, Jewetz E. International Edition. Singapore, p. 286–294.
9. Levy JA (1994). Intracellular Control of HIV replication. In: HIV and the Pathogenesis of AIDS. ASM press, Washington DC, p. 59–70.
10. Luzuriaga K, Sullivan JL (1997). Transmission of the human
immunodeficiency virus from mother to the fetus and infant. In: AIDS etiology, diagnosis, treatment and prevention. Fourth Edition. Editor: DeVita VT, Hellman S, Rosenberg SA. Philadelphia, p. 167–173.
11. Mandel GL (2000). Human immunodeficiency virus. In: Essential
atlas of infectious diseases, 2nd ed. Editor : Bleck TP, Brook I, Fekety
R, Lorber B, Mildvan D. Philadelphia: Current Medicine, Inc, p. 6–7.
12. Metcalf JA, Davey RT, Lane HC (1997). Acquired Immunodeficiency Syndrome: Serologic and Virologic Tests. In: AIDS. Fourth Edition. Editors: DeVita VT, Hellman S, Rosernbrk SA. Lippincott – Raven, Philadelphia, p. 177–195.
13. Money D, 2003. HIV and pregnancy. From: http://www.bcpwa.
org/issue6/HIVPreg.htm Accessted 10/28/2003.
14. Oppenheim JJ, Ruscetti FW, (2003). Cytokines. In: Medical
immunology. Tenth ed. Editors: Parslow TG, Stites Dp, Terr AI,
Imboden JB, .International edition, San Fransisco, p. 48–166.
15. Rantam, FA, Ferdiansyah, Nasronudin, Purwati, (2009). Stem Cells and Exploration, Airlangga University Press.
16. Sriram B, Rammmesh A (2008). Human embryonic stemcell (hES) derived dendritic cells are functionally normal and are suspectible to HIV-1 in. AIDS Research and Therapy.
17. Suwendra P (2002). Human Immunodeficiency Virus. Dalam: Buku Ajar Ilmu Kesehatan Anak infeksi dan Penyakit Tropis. Edisi pertama. Editor: Soedarmo S, Garna H, Hadinegoro SR. Ikatan Dokter Anak Indonesia, Jakarta, hlm. 281–302
18. UNAIDS/WHO (2002). AIDS epidemic update. Joint United Nations Programe on HIV & AIDS and World Health Organization, Genewa, p. 1–42.
19. Viviani B, Corsini E, Binaglia M, Galli CL, Marinovich M (2001).
Reactive oxygen species generated by glia are responsible for neuron
death induced by human immunodeficiency virus-glycoprotein 120
in vitro. Neuroscience 107: 2–24.
20. WHO (2002). The use of antiretrviral therapy: A simplified approach for resource-constrained countries.WHO regional office for SouthEast Asia, New Delhi, pp. 1–49.
21. Wolf T, Rickerts V, Staszewski S (2007). First Case of successful
allogenic stem cell transplantation in an HIV-patient who acquired severe Aplastic Anemia. Haematologica, Vol 92, Issue 4, e56-e58 doi:10.3324/haematol.11394
22. Zhang YM, Hartzell C, Narlow M (2002). Stem cells derived
cardiomyocites demonstrate arrytmic potential. Circulation, 106:
1294–99.
The Indonesian Journal of Tropical and Infectious Disease (IJTID) is a scientific peer-reviewed journal freely available to be accessed, downloaded, and used for research. All articles published in the IJTID are licensed under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License, which is under the following terms:
Attribution ” You must give appropriate credit, link to the license, and indicate if changes were made. You may do so reasonably, but not in any way that suggests the licensor endorses you or your use.
NonCommercial ” You may not use the material for commercial purposes.
ShareAlike ” If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
No additional restrictions ” You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
